NLX 101
Alternative Names: F15599; NLX-101Latest Information Update: 05 Feb 2025
At a glance
- Originator Pierre Fabre
- Developer Neurolixis
- Class Antidementias; Antidepressants; Antipsychotics; Piperidines; Pyrimidines; Small molecules
- Mechanism of Action 5-HT1A serotonin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Fragile X syndrome
- No development reported Depressive disorders; Rett syndrome
- Discontinued Cognition disorders; Mood disorders; Schizophrenia
Most Recent Events
- 24 Jan 2025 NLX 101 receives Orphan Drug status for Fragile X syndrome
- 28 Sep 2024 No recent reports of development identified for phase-I development in Rett syndrome(In volunteers) in USA (PO)
- 28 Sep 2024 No recent reports of development identified for preclinical development in Depressive disorders in USA